Last reviewed · How we verify
IV Antibacterial Agents
IV antibacterial agents kill or inhibit the growth of bacteria through various mechanisms including cell wall disruption, protein synthesis inhibition, or DNA damage.
IV antibacterial agents kill or inhibit the growth of bacteria through various mechanisms including cell wall disruption, protein synthesis inhibition, or DNA damage. Used for Bacterial infections requiring intravenous administration (broad spectrum).
At a glance
| Generic name | IV Antibacterial Agents |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antibacterial agent (broad category) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a broad category encompassing multiple classes of intravenous antibiotics (e.g., beta-lactams, aminoglycosides, fluoroquinolones, glycopeptides) that work through distinct mechanisms. Common mechanisms include inhibition of bacterial cell wall synthesis, disruption of protein translation, or interference with nucleic acid replication. The specific mechanism depends on the individual antibiotic within this class.
Approved indications
- Bacterial infections requiring intravenous administration (broad spectrum)
Common side effects
- Hypersensitivity reactions
- Nephrotoxicity
- Ototoxicity
- Gastrointestinal disturbances
- Phlebitis at injection site
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Regular Home-use of Dual-light Photodynamic Therapy in the Management of Chronic Stage III-IV Periodontitis (NA)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Evaluating Postoperative Pain and Antibacterial Effect of Ultrasonic and 980 nm Diode Laser Combination (NA)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia) (NA)
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Antibacterial Agents CI brief — competitive landscape report
- IV Antibacterial Agents updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI